SLC5A2 and coronary artery disorder: In extensive CAD, Chipayo-Gonzales et al. found reduced all-cause mortality (HR = 0.34) with SGLT2 inhibitors initiation at discharge and a trend toward lower CV mortality with no statistical significance [35].